# US Blood Group Typing Market

> US Blood Group Typing Market Research Report: Size, Share, Trend Analysis By Technology (Molecular Typing, Serological Typing, Microarray-based Typing, Next-generation Sequencing), By Product Type (Reagents, Instruments, Software, Consumables), By Applications (Transfusion Medicine, Transplantation, Forensic Science, Research) and By End Use (Blood Banks, Hospitals, Diagnostic Laboratories, Academic Institutions) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.83%
- **2024:** $ 523.71 Million
- **2025:** $ 564.72 Million
- **2035:** $ 1,200 Million
- **Key Players:** Thermo Fisher Scientific (US), Abbott Laboratories (US), Roche Diagnostics (CH), Grifols (ES), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), Beckman Coulter (US), Merck KGaA (DE), Siemens Healthineers (DE)

**Report ID:** MRFR/MED/13964-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-blood-group-typing-market-15491

---

## Market Summary

## **US Blood Group Typing Market Overview**

As per MRFR analysis, the US Blood Group Typing Market Size was estimated at 480.17 (USD Million) in 2023. The US Blood Group Typing Market Industry is expected to grow from 600(USD Million) in 2024 to 1,500 (USD Million) by 2035. The US Blood Group Typing Market CAGR (growth rate) is expected to be around 8.687% during the forecast period (2025 - 2035).

### **Key US Blood Group Typing Market Trends Highlighted**

The US Blood Group Typing Market is experiencing significant advancements, driven by increasing demand for blood donations and the need for accurate blood typing in medical procedures. As hospitals and blood banks prioritize patient safety, the focus on precision in blood group typing has intensified. The ongoing development of rapid testing technologies is also a key market driver, facilitating quicker results for healthcare providers and enhancing the efficiency of blood transfusion processes. Moreover, the rising prevalence of blood-related diseases, such as hemophilia and thalassemia, is pushing healthcare facilities to implement advanced blood typing solutions that ensure compatibility and safety.

Opportunities to be explored in the US market include the integration of automation and artificial intelligence in blood typing procedures. These technologies have the potential to streamline operations and reduce human error, creating a more reliable environment for blood typing and transfusions. Additionally, as personalized medicine becomes more significant in the healthcare landscape, there is potential for growth in developing tailored blood typing solutions that cater to specific patient needs. Recent trends indicate a shift towards the use of non-invasive blood typing methods, which can enhance patient comfort and reduce the risk of complications associated with traditional methods.

Furthermore, educational campaigns promoting blood donation are becoming increasingly popular, reinforcing the importance of diverse blood group representation and encouraging individuals to participate in donation drives. These trends highlight a commitment to improving blood safety and efficiency in the US medical system, paving the way for a more robust and responsive blood group typing market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Blood Group Typing Market Drivers**

### **Increasing Demand for Blood Transfusion Services**

The rising incidence of surgeries and trauma cases in the United States necessitates a robust demand for blood transfusion services, which directly influences the US Blood Group Typing Market Industry. According to the American Hospital Association, approximately 14 million blood transfusions are performed each year in the U.S., indicating an increasing need for blood compatibility testing. Furthermore, with the aging population leading to more medical procedures, the National Institute on Aging projects that by 2035, there will be about 78 million older adults in the U.S., emphasizing the urgent requirement for efficient blood typing and testing services.

Major organizations like the American Red Cross are actively promoting blood donations and ensuring the availability of safe blood, thereby expanding the market for blood group typing.

### **Technological Advancements in Blood Group Typing**

Technological innovations play a crucial role in enhancing the accuracy and efficiency of blood group typing. Recent advancements such as molecular typing and automated blood typing systems are becoming more prevalent within laboratories. The Centers for Disease Control and Prevention highlights that rapid testing and high-throughput typing methods can significantly minimize errors and improve turnaround times for blood compatibility testing. Companies like Ortho Clinical Diagnostics are developing state-of-the-art blood typing solutions that cater to hospitals and blood banks, fostering growth in the US Blood Group Typing Market Industry.

### **Growth in Blood Donation Awareness Initiatives**

There is a marked increase in awareness programs aimed at encouraging blood donations in the United States. Organizations such as the American Red Cross have launched campaigns focused on educating the public about the importance of blood donation. According to the Health Resources and Services Administration, nearly 5% of the U.S. population donates blood each year, which is a vital statistic for maintaining blood supply and necessitating rigorous blood typing practices.

Increased blood donations not only support patient care but also stimulate demand for more precise blood typing services in the US Blood Group Typing Market Industry.

### **Rising Incidence of Hematological Disorders**

The prevalence of hematological disorders such as anemia and hemophilia in the United States is a significant driver for the US Blood Group Typing Market Industry. The National Heart, Lung, and Blood Institute estimates that over 3 million Americans suffer from anemia, underscoring the need for precise blood typing to ensure accurate diagnoses and treatment plans. Also, with the growing recognition of these conditions, there is a concurrent increase in the demand for routine blood group typing and cross-matching, propelling market growth further.

## **US Blood Group Typing Market Segment Insights**

### **Blood Group Typing Market Technology Insights**

The Technology segment within the US Blood Group Typing Market encompasses various advanced methodologies essential for accurately identifying blood groups, which play a critical role in transfusion medicine and safe transplantation. Each of the methods contributes uniquely to the efficiency and reliability of blood typing, responding directly to the healthcare industry's increasing demand for precise diagnostic tools. Molecular Typing utilizes techniques based on DNA analysis, offering high-resolution results that are invaluable for matching blood donors with recipients, addressing genetic variations that may affect compatibility.

This method is particularly significant in scenarios requiring highly accurate typing, such as organ transplants, reflecting the growing trend toward personalized medicine. Serological Typing, on the other hand, has remained a staple approach, primarily relying on antigen-antibody reactions to determine blood type. Its widespread use in clinical laboratory settings signifies the robustness and reliability of serological methods, making it a dominantly trusted procedure for routine blood typing due to its established protocols and accessibility.

Moreover, Microarray-based Typing is gaining traction by allowing simultaneous analysis of multiple blood group antigens, providing a more comprehensive profile of blood types. This technology not only enhances operational efficiency but also ensures accuracy in blood grouping by minimizing human error. Next-generation Sequencing represents the forefront of technology, offering unprecedented detail in blood group typing through comprehensive genomic data analysis, thereby expanding the possibilities for identifying rare blood types and developing more targeted blood transfusion strategies.

As the US Blood Group Typing Market continues to evolve, these technological advancements are driving growth and transforming the landscape of transfusion practices, highlighting the importance of integrating innovative solutions in healthcare to fulfill increasing patient safety demands and improve outcomes.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Blood Group Typing Market Product Type Insights**

The US Blood Group Typing Market showcases a diverse array of Product Types, primarily comprising Reagents, Instruments, Software, and Consumables. Reagents play a crucial role as essential components in blood typing procedures; they enable accurate identification of blood groups, which is vital for transfusions and organ transplants. Instruments, including automated analyzers, are increasingly significant as they improve efficiency and reliability in laboratories, addressing demands for faster results. Software solutions are becoming integral in managing blood typing processes and enhancing data accuracy, thus supplementing laboratory automation and patient safety.

Consumables, which include items like blood bags and test plates, support the overall workflow in blood typing, ensuring that essential supplies are readily available. The trend towards more advanced and integrated solutions within the Product Type segment reflects the industry's focus on improving diagnostic precision, streamlining operations, and enhancing patient outcomes in the US healthcare system. This concerted push towards technological advancements and innovation in the US Blood Group Typing Market is expected to drive growth and responsiveness to clinical needs, ultimately shaping its landscape in the coming years.

### **Blood Group Typing Market Application Insights**

The Application segment of the US Blood Group Typing Market plays a vital role in ensuring patient safety and efficient medical procedures. Transfusion Medicine leads this sector, with rigorous blood typing practices essential for preventing transfusion reactions, thereby enhancing patient outcomes. Furthermore, Transplantation relies heavily on accurate blood group identification to match donors and recipients, minimizing the risk of graft rejection and other complications. Forensic Science utilizes blood typing techniques to aid in criminal investigations, providing critical evidence for solving cases.

Research functions as a backbone for advancements in blood group typing technologies, driving innovations that enhance precision and efficiency within the healthcare ecosystem. With growing awareness of the importance of ensuring the correct blood typing in these applications, the market is expected to witness consistent growth driven by technological advancements, increased funding in healthcare sectors, and a rising demand for blood products. The US Blood Group Typing Market is positioned to address these needs, aiming to optimize the safety and effectiveness of blood-related medical practices across various applications.

### **Blood Group Typing Market End Use Insights**

The US Blood Group Typing Market is characterized by a diverse array of end-use applications, primarily including Blood Banks, Hospitals, Diagnostic Laboratories, and Academic Institutions. Blood Banks play a critical role in maintaining a steady supply of safe blood, necessitating precise blood typing to prevent transfusion reactions; thus, they are a significant driver of growth in this market. Hospitals rely heavily on accurate blood group typing for efficient management of surgeries and emergency transfusions, further underlining the segment's importance.

Diagnostic Laboratories serve as essential hubs for testing and analysis, ensuring that patients receive timely and accurate blood type evaluations. Lastly, Academic Institutions contribute to the evolution of this market through Research and Development initiatives, fostering innovation in blood typing technologies. Overall, these end-use segments underscore the vital role that blood group typing plays in healthcare and the ongoing demand for advanced typing solutions within the US Blood Group Typing Market.

The focus on safety and efficiency, along with advancements in technology, highlights the dynamic nature of this industry segment and its significant contributions to improved patient outcomes across the healthcare spectrum.

## **US Blood Group Typing Market Key Players and Competitive Insights**

The US Blood Group Typing Market is characterized by a dynamic landscape driven by advancements in technology, increasing demand for safe blood transfusions, and the growth of genetic testing. The market features a variety of players ranging from established pharmaceutical companies to innovative biotech firms that offer a range of blood typing solutions. Competitive insights reveal a focus on the development of cutting-edge blood typing reagents, automated systems, and comprehensive testing solutions that enhance accuracy and efficiency in blood typing processes.

Companies in this market are also leveraging strategic partnerships and collaborations to enhance their product offerings and expand their market reach. Furthermore, the regulatory environment plays a significant role in shaping competition, as firms strive to comply with stringent guidelines while driving innovation in blood typing methodologies.

Novartis has established a significant presence in the US Blood Group Typing Market, capitalizing on its extensive research and development capabilities. The company’s strengths lie in its innovative approaches to blood typing technologies and a robust product portfolio that addresses various needs within the healthcare system. With a focus on improving patient safety and enhancing the accuracy of blood group determinations, Novartis leverages advanced analytical methods and automation in their offerings. The company's commitment to quality and reliability further strengthens its position, allowing it to foster trust with healthcare providers and blood banks across the United States.

Initiatives aimed at continuous improvement and adherence to regulatory standards solidify Novartis’s competitive advantage in this sector while meeting the evolving demands of the market.

BioRad Laboratories is another key player in the US Blood Group Typing Market, well-known for its comprehensive range of products and services tailored to blood typing applications. The company specializes in providing dedicated blood typing reagents, automated systems, and diagnostic kits that ensure high accuracy in blood compatibility testing. BioRad’s strong market presence is bolstered by its commitment to innovation, evident through continual investment in research and development. This enables the company to introduce advanced solutions that meet the clinical needs of blood banks and transfusion centers.

BioRad has also strategically engaged in mergers and acquisitions to enhance its technological capabilities and expand its product offerings within the US market. The company's robust distribution network, combined with strong customer support initiatives, further strengthens its position in the competitive landscape of blood group typing in the United States.

### **Key Companies in the US Blood Group Typing Market Include**

## **US Blood Group Typing Market Industry Developments**

Recent developments in the US Blood Group Typing Market have shown vigorous growth driven by technological advancements and increasing demand for safe blood transfusions. Companies like Novartis, BioRad Laboratories, and Abbott Laboratories are enhancing their offerings through substantial investments in Research and Development. In November 2022, Grifols announced a partnership with Asuragen to expand their diagnostic solutions, highlighting collaborations aimed at improving testing accuracy and efficiency. Additionally, in early 2022, Thermo Fisher Scientific acquired a leading blood typing technology firm, aiming to enhance its product portfolio and customer reach.

The overall market has seen a valuation increase owing to the surge in blood donation drives and an aging population necessitating blood products. Furthermore, a notable trend is the growing focus on automation and digital health in labs, spurred on by innovations from companies like Beckman Coulter and Sysmex America. Within the last two years, regulations by the US Food and Drug Administration have intensified, with a focus on ensuring the safety and efficacy of blood typing tests, further shaping the landscape of the market for years to come.

## **US Blood Group Typing Market Segmentation Insights**

### **Blood Group Typing Market Technology Outlook**

### **Blood Group Typing Market Product Type Outlook**

### **Blood Group Typing Market Application Outlook**

### **Blood Group Typing Market End Use Outlook**

## Market Drivers

### Regulatory Support for Blood Safety

Regulatory bodies in the US are increasingly emphasizing blood safety, which is influencing the blood group-typing market. The Food and Drug Administration (FDA) has implemented stringent guidelines for blood collection and transfusion practices, mandating accurate blood typing to prevent transfusion reactions. As a result, healthcare providers are investing in advanced blood typing technologies to comply with these regulations. The blood group-typing market is expected to benefit from this regulatory environment, as adherence to safety standards drives demand for reliable and efficient blood typing solutions. Furthermore, ongoing updates to regulations may lead to the development of innovative products that enhance blood safety, further stimulating market growth.

### Rising Prevalence of Blood Disorders

The increasing incidence of blood disorders such as anemia, hemophilia, and thalassemia is driving the blood group-typing market. According to the Centers for Disease Control and Prevention (CDC), approximately 3 million individuals in the US are affected by anemia alone. This growing patient population necessitates accurate blood typing for effective treatment and management. As healthcare providers seek to enhance patient outcomes, the demand for reliable blood group-typing solutions is expected to rise. Furthermore, advancements in diagnostic technologies are likely to improve the accuracy and speed of blood typing, further propelling market growth. The blood group-typing market is thus positioned to benefit from this trend, as healthcare systems increasingly prioritize precise diagnostics to address the needs of patients with blood-related conditions.

### Expansion of Blood Donation Initiatives

The expansion of blood donation initiatives across the US is significantly impacting the blood group-typing market. Organizations such as the American Red Cross are actively promoting blood donation drives, which have seen a notable increase in participation. In 2025, it is estimated that blood donations will rise by approximately 15%, necessitating efficient blood group-typing to ensure compatibility for transfusions. This surge in donations creates a corresponding demand for blood typing services, as healthcare facilities must accurately match donors with recipients. The blood group-typing market is likely to experience growth as a result of these initiatives, as they not only enhance the availability of blood products but also emphasize the importance of accurate blood typing in transfusion medicine.

### Technological Integration in Healthcare

The integration of advanced technologies in healthcare is reshaping the blood group-typing market. Innovations such as artificial intelligence (AI) and machine learning are being utilized to enhance the accuracy and efficiency of blood typing processes. For instance, AI algorithms can analyze blood samples more rapidly than traditional methods, potentially reducing turnaround times by up to 30%. This technological advancement not only improves patient care but also streamlines laboratory operations. As healthcare facilities increasingly adopt these technologies, the blood group-typing market is likely to experience significant growth. The potential for improved diagnostic capabilities and operational efficiencies positions the market favorably in the evolving healthcare landscape.

### Growing Awareness of Blood Type Compatibility

There is a growing awareness among the public regarding the importance of blood type compatibility in medical procedures, which is positively influencing the blood group-typing market. Educational campaigns and health initiatives are informing individuals about the critical role of blood typing in transfusions and organ transplants. This heightened awareness is likely to lead to an increase in demand for blood typing services, as patients and healthcare providers prioritize compatibility to avoid adverse reactions. The blood group-typing market stands to gain from this trend, as the emphasis on patient safety and informed decision-making drives the need for accurate blood typing solutions.

## Future Outlook

The [Blood Group Typing Market](https://www.marketresearchfuture.com/reports/blood-group-typing-market-6410) is projected to grow at a 7.83% CAGR from 2025 to 2035, driven by technological advancements and increasing demand for blood transfusions.

**New opportunities:**

- Development of mobile blood typing units for remote areas. Integration of AI-driven analytics for faster results. Expansion of partnerships with healthcare providers for on-site testing.

By 2035, the market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Technology: Molecular Typing (Largest) vs. Next-generation Sequencing (Fastest-Growing)

In the US blood group-typing market, Molecular Typing holds the largest market share due to its accuracy and efficiency in determining blood types. Following closely, Serological Typing presents a significant, albeit smaller, share. Microarray-based Typing and Next-generation Sequencing are also relevant but occupy niche positions within the market, catering to specific laboratory needs and research applications.

Recent trends indicate that the technology segment is poised for robust growth, with Next-generation Sequencing emerging as the fastest-growing segment. This growth is driven by increased demand for precise diagnostics, technological advancements, and a shift towards personalized medicine. Integration of these technologies into routine practice is transforming blood group-typing and enabling faster, more reliable results.

Molecular Typing: Dominant vs. Next-generation Sequencing: Emerging

Molecular Typing, characterized by its robust methodology and high reliability, dominates the US blood group-typing market. It appeals to a wide range of healthcare settings, offering tested accuracy and speed in blood typing processes. In contrast, Next-generation Sequencing is gaining traction as an emerging alternative, promising enhanced depth of analysis and the ability to decode more complex blood types. As the need for more sophisticated typing methods grows, especially in transfusion medicine and genetic research, the position of Next-generation Sequencing is advancing rapidly, attracting investment and innovation.

### By Product Type: Reagents (Largest) vs. Instruments (Fastest-Growing)

In the US blood group-typing market, reagents dominate the product type segment, holding a significant share due to their essential role in the testing and analysis processes. Following reagents, instruments are also vital as they enable the automation of blood typing tests, thereby streamlining workflows within healthcare facilities. Software and consumables, while important, comprise a smaller portion of the market share, serving primarily supporting roles in the overall blood typing process.

In terms of growth trends, instruments are emerging as the fastest-growing segment, driven by technological advancements and the increasing need for efficient diagnostic solutions. The rising incidence of blood disorders and the demand for rapid blood typing are key factors fueling the growth of this segment. Reagents, on the other hand, continue to be a consistent player due to the ongoing requirements for reliable testing, though growth rates may not match those of instruments.

Reagents (Dominant) vs. Software (Emerging)

Reagents are the dominant force in the blood group-typing product type segment, recognized for their critical role in ensuring accurate blood typing results. Their reliable performance in various testing scenarios makes them indispensable in laboratories and healthcare settings, particularly as accuracy is paramount in blood transfusion and compatibility testing. In contrast, software is emerging as a vital component in the market, offering innovative solutions to enhance data management and analysis, thereby increasing efficiency. This segment is gaining traction as healthcare organizations seek to integrate advanced technologies to streamline operations and improve service delivery. The dual focus on reagents and software illustrates the dynamic nature of this market, where traditional practices complement cutting-edge advancements.

### By Application: Transfusion Medicine (Largest) vs. Forensic Science (Fastest-Growing)

In the US blood group-typing market, Transfusion Medicine holds the largest share, driven by its critical role in ensuring safe blood transfusions. Followed by Transplantation, which also constitutes a significant portion of the market, Forensic Science is gaining traction with its increasing applications in criminal investigations. Research activities closely follow, emphasizing the continuous need for advancements in blood typing technologies and methodologies.

The growth trends for these segments reveal dynamic shifts, with Forensic Science emerging as the fastest-growing sector due to heightened awareness of forensic analyses in legal cases. Meanwhile, Transfusion Medicine remains robust with steady growth driven by advancements in blood safety protocols and the rising demand for blood products in healthcare facilities, highlighting the importance of accurate blood typing processes across various applications.

Transfusion Medicine (Dominant) vs. Forensic Science (Emerging)

Transfusion Medicine stands as the dominant application within the market, essential for safe and effective blood transfusions in various medical procedures. It benefits from advanced technologies that ensure the accuracy of blood typing, thereby minimizing risks associated with transfusion-related complications. On the other hand, Forensic Science is an emerging application, rapidly gaining importance due to increasing crime rates and the subsequent demand for reliable forensic evidence. This segment is characterized by innovative techniques and technologies tailored for precise blood identification in criminal investigations and paternity testing. As the awareness and need for forensic applications expand, Forensic Science is expected to secure a larger market position, balancing the dominance of Transfusion Medicine.

### By End-Use: Blood Banks (Largest) vs. Hospitals (Fastest-Growing)

In the US blood group-typing market, the distribution of market share reveals that Blood Banks hold the largest portion due to their critical role in the healthcare system, ensuring a steady supply of blood products. Hospitals follow closely, capitalizing on their increasing demand for safe transfusions and testing services. Diagnostic Laboratories and Academic Institutions occupy smaller stakes in this market, but their contributions should not be underestimated as they support essential research and diagnostics.

Growth trends indicate that Hospitals are emerging as the fastest-growing segment driven by technological advancements and increased awareness about blood safety. Factors such as rising surgical procedures, an aging population requiring transfusions, and a shift towards personalized medicine are propelling this growth. Blood Banks continue to dominate, but the rapid expansion of healthcare services in hospitals is reshaping the landscape in favor of improved blood typing methodologies.

Blood Banks (Dominant) vs. Hospitals (Emerging)

Blood Banks play a dominant role in the US blood group-typing market due to their foundational contributions to blood storage, processing, and distribution. They ensure compliance with stringent regulations and offer various typing services to enhance safety in transfusions. In contrast, Hospitals represent an emerging segment as they adopt advanced blood typing technologies to improve patient outcomes. Their investments in automation and digital solutions are rapidly evolving, enabling them to keep pace with increasing demands for accuracy and efficiency in blood transfusion practices. Both segments are integral, yet they cater to different aspects of patient care and public health.

## Competitive Benchmarking

The blood group-typing market in the US is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and technological advancements. Key players such as Thermo Fisher Scientific (US), Abbott Laboratories (US), and Roche Diagnostics (CH) are at the forefront, each adopting distinct strategies to enhance their market presence. Thermo Fisher Scientific (US) focuses on expanding its product portfolio through continuous innovation, particularly in molecular diagnostics, which appears to be a significant growth area. Meanwhile, Abbott Laboratories (US) emphasizes strategic acquisitions to bolster its capabilities in blood testing technologies, thereby enhancing its competitive edge. Roche Diagnostics (CH) is also investing heavily in digital transformation initiatives, aiming to streamline operations and improve customer engagement, which collectively shapes a dynamic competitive environment.The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure is moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. This competitive structure allows for a diverse range of products and services, catering to various customer needs while fostering innovation across the sector.
In October Abbott Laboratories (US) announced the acquisition of a leading blood testing technology firm, which is expected to enhance its diagnostic capabilities significantly. This strategic move not only strengthens Abbott's position in the blood group-typing market but also aligns with its broader goal of expanding its portfolio in precision medicine. The acquisition is likely to facilitate the development of more advanced testing solutions, thereby improving patient outcomes and solidifying Abbott's competitive stance.
In September Thermo Fisher Scientific (US) launched a new line of automated blood typing systems designed to increase throughput and accuracy in laboratory settings. This innovation is particularly relevant as it addresses the growing demand for efficient and reliable blood testing solutions. By enhancing operational efficiency, Thermo Fisher aims to capture a larger market share and respond effectively to the evolving needs of healthcare providers.
In August Roche Diagnostics (CH) unveiled a digital platform that integrates AI-driven analytics into its blood testing processes. This platform is designed to provide real-time insights and predictive analytics, which could significantly improve decision-making in clinical settings. The integration of AI not only positions Roche as a leader in technological advancement but also reflects a broader trend towards digitalization in the healthcare sector.
As of November the competitive trends in the blood group-typing market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing operational capabilities. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and adapt to changing market dynamics.

## Recent News & Developments

Recent developments in the US Blood Group Typing Market have shown vigorous growth driven by technological advancements and increasing demand for safe blood transfusions. Companies like Novartis, BioRad Laboratories, and Abbott Laboratories are enhancing their offerings through substantial investments in Research and Development. In November 2022, Grifols announced a partnership with Asuragen to expand their diagnostic solutions, highlighting collaborations aimed at improving testing accuracy and efficiency. Additionally, in early 2022, Thermo Fisher Scientific acquired a leading blood typing technology firm, aiming to enhance its product portfolio and customer reach.

The overall market has seen a valuation increase owing to the surge in blood donation drives and an aging population necessitating blood products. Furthermore, a notable trend is the growing focus on automation and digital health in labs, spurred on by innovations from companies like Beckman Coulter and Sysmex America. Within the last two years, regulations by the US Food and Drug Administration have intensified, with a focus on ensuring the safety and efficacy of blood typing tests, further shaping the landscape of the market for years to come.

## Report Scope

| MARKET SIZE 2024 | 523.71(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 564.72(USD Million) |
| MARKET SIZE 2035 | 1200.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.83% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Thermo Fisher Scientific (US), Abbott Laboratories (US), Roche Diagnostics (CH), Grifols (ES), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), Beckman Coulter (US), Merck KGaA (DE), Siemens Healthineers (DE) |
| Segments Covered | Technology, Product Type, Application, End-Use |
| Key Market Opportunities | Advancements in rapid testing technologies enhance accuracy and efficiency in the blood group-typing market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation in the blood group-typing market, enhancing accuracy and efficiency. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US blood group-typing market?**
A: The market valuation was $523.71 Million in 2024.

**Q: What is the projected market size for the US blood group-typing market by 2035?**
A: The market is projected to reach $1200.0 Million by 2035.

**Q: What is the expected CAGR for the US blood group-typing market during the forecast period 2025 - 2035?**
A: The expected CAGR is 7.83% during the forecast period 2025 - 2035.

**Q: Which companies are the key players in the US blood group-typing market?**
A: Key players include Thermo Fisher Scientific, Abbott Laboratories, Roche Diagnostics, and others.

**Q: What are the main technology segments in the US blood group-typing market?**
A: Main technology segments include Molecular Typing, Serological Typing, Microarray-based Typing, and Next-generation Sequencing.

**Q: How much revenue did the Serological Typing segment generate in 2024?**
A: The Serological Typing segment generated $200.0 Million in 2024.

**Q: What is the revenue range for Diagnostic Laboratories as an end-use segment?**
A: The revenue range for Diagnostic Laboratories is $200.0 Million to $450.0 Million.

**Q: What product types are included in the US blood group-typing market?**
A: Product types include Reagents, Instruments, Software, and Consumables.

**Q: What applications are driving the demand in the US blood group-typing market?**
A: Applications driving demand include Transfusion Medicine, Transplantation, Forensic Science, and Research.

**Q: What is the revenue range for the Next-generation Sequencing technology segment?**
A: The revenue range for the Next-generation Sequencing segment is $73.71 Million to $200.0 Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-blood-group-typing-market-15491*